HUP0300626A2 - Progesztogén és mifepriszton alkalmazása rákellenes gyógyszerkészítmények előállítására - Google Patents

Progesztogén és mifepriszton alkalmazása rákellenes gyógyszerkészítmények előállítására

Info

Publication number
HUP0300626A2
HUP0300626A2 HU0300626A HUP0300626A HUP0300626A2 HU P0300626 A2 HUP0300626 A2 HU P0300626A2 HU 0300626 A HU0300626 A HU 0300626A HU P0300626 A HUP0300626 A HU P0300626A HU P0300626 A2 HUP0300626 A2 HU P0300626A2
Authority
HU
Hungary
Prior art keywords
progestogen
mifepristone
preparation
pharmaceutical compositions
anticancer pharmaceutical
Prior art date
Application number
HU0300626A
Other languages
English (en)
Inventor
Kevin Gaston
Original Assignee
The University Of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Bristol filed Critical The University Of Bristol
Publication of HUP0300626A2 publication Critical patent/HUP0300626A2/hu
Publication of HUP0300626A3 publication Critical patent/HUP0300626A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya szteroid hormon vagy szteroid hormon analóg éslegalább egy rész HPV E2 protein alkalmazása gyógyszer előállítására,amellyel méhnyakrák kezelhető. A találmány közelebbről progesztogén,RU486 (mifepriszton) vagy RU486-származék alkalmazására vonatkozikgyógyszer előállítására, amellyel méhnyakrák kezelhető vagyenyhíthető. Ó
HU0300626A 2000-05-03 2001-05-03 Use of progestogen and mifepristone for preparation of anticancer pharmaceutical compositions HUP0300626A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0010683.1A GB0010683D0 (en) 2000-05-03 2000-05-03 Cancer therapy
PCT/GB2001/001941 WO2001082910A2 (en) 2000-05-03 2001-05-03 Combination of progesterone and mifepristone for cancer therapy

Publications (2)

Publication Number Publication Date
HUP0300626A2 true HUP0300626A2 (hu) 2003-07-28
HUP0300626A3 HUP0300626A3 (en) 2003-12-29

Family

ID=9890890

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300626A HUP0300626A3 (en) 2000-05-03 2001-05-03 Use of progestogen and mifepristone for preparation of anticancer pharmaceutical compositions

Country Status (13)

Country Link
US (1) US20040102422A1 (hu)
EP (1) EP1278523B1 (hu)
JP (1) JP2003531852A (hu)
AT (1) ATE270554T1 (hu)
AU (1) AU6042201A (hu)
CA (1) CA2407134A1 (hu)
CZ (1) CZ20023585A3 (hu)
DE (1) DE60104194T2 (hu)
GB (1) GB0010683D0 (hu)
HU (1) HUP0300626A3 (hu)
NO (1) NO20025157L (hu)
PL (1) PL365755A1 (hu)
WO (1) WO2001082910A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535624A (ja) * 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療におけるシクロチオカルバメート誘導体の使用
EA200500210A1 (ru) 2002-07-16 2005-06-30 Медексис С. А. Конъюгаты стероидов, их получение и их применение
GR1004274B (el) * 2002-07-16 2003-06-23 Medexis ���� Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
WO2007079128A1 (en) * 2005-12-30 2007-07-12 Ventana Medical Systems, Inc. Na+, k+-atpase expression in cervical dysplasia and cancer
WO2012138857A2 (en) 2011-04-08 2012-10-11 Mayo Foundation For Medical Education And Research Methods and materials for reducing supression of immune function
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP3275888B1 (en) 2016-07-28 2019-09-25 Council of Scientific & Industrial Research Progesterone-cationic lipid hybrid as anticancer agent and the process of synthesis thereof
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
KR102544591B1 (ko) * 2023-02-08 2023-07-17 주식회사 에스씨엘테라퓨틱스 신규 화합물 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
DE4330234A1 (de) * 1993-09-02 1995-03-09 Schering Ag Verwendung von Gestagenen und kompetitiven Progesteronantagonisten zur Herstellung von Arzneimitteln für die weibliche Fertilitätskontrolle sowie Mittel enthaltend ein Gestagen und einen kompetitiven Progesteronantagonisten

Also Published As

Publication number Publication date
EP1278523A2 (en) 2003-01-29
AU6042201A (en) 2001-11-12
ATE270554T1 (de) 2004-07-15
GB0010683D0 (en) 2000-06-28
HUP0300626A3 (en) 2003-12-29
CZ20023585A3 (cs) 2003-04-16
NO20025157L (no) 2002-12-02
DE60104194T2 (de) 2005-08-04
JP2003531852A (ja) 2003-10-28
PL365755A1 (en) 2005-01-10
CA2407134A1 (en) 2001-11-08
EP1278523B1 (en) 2004-07-07
WO2001082910A3 (en) 2002-09-06
US20040102422A1 (en) 2004-05-27
WO2001082910A2 (en) 2001-11-08
NO20025157D0 (no) 2002-10-25
DE60104194D1 (de) 2004-08-12

Similar Documents

Publication Publication Date Title
HUP0300626A2 (hu) Progesztogén és mifepriszton alkalmazása rákellenes gyógyszerkészítmények előállítására
HUP0302093A2 (hu) Konjugált ösztrogének és medroxi-progeszteron-acetát alkalmazása hormonpótló terápiában használható gyógyszerkészítmény előállítására
DK0748190T3 (da) Progestogenfrie formuleringer af GnRH og estrogen til behandling af benigne gynækologiske lidelser
NO20091954L (no) Anvendelse av ostradiolvalerat eller 17ß-ostradil i kombinasjon med dienogest for oral terapi for opprettholdelse og/eller okning av kvinnelig libido
DK1443966T3 (da) Fremgangsmåde til forebyggelse eller behandling af benigne gynækologiske lidelser
CA2334702A1 (en) Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol
HUP0301460A2 (hu) Antiprogresztinek használata hormonfüggő betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállításához
HUP0402142A2 (hu) Kombinációs ösztrogén-gestagen készítmény és alkalmazása
TW200514560A (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
DE60330695D1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
SG153645A1 (en) Hormone replacement therapy
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
IL164159A0 (en) C-17 spirolactonization and 6,7 oxidation of steroids
HUP9903747A2 (hu) Új eljárás mometazon-furoát előállítására
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
DE69525181D1 (de) Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
CR6627A (es) Nuevo medicamento contraceptivo y su modo de preparacion
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti